3,032 Shares in Legend Biotech Co. (NASDAQ:LEGN) Bought by Quantbot Technologies LP

Quantbot Technologies LP acquired a new stake in Legend Biotech Co. (NASDAQ:LEGN) during the third quarter, according to its most recent filing with the SEC. The firm acquired 3,032 shares of the company’s stock, valued at approximately $148,000.

Several other institutional investors also recently bought and sold shares of LEGN. Avior Wealth Management LLC boosted its holdings in shares of Legend Biotech by 3.0% in the third quarter. Avior Wealth Management LLC now owns 11,097 shares of the company’s stock valued at $541,000 after acquiring an additional 323 shares in the last quarter. Public Sector Pension Investment Board increased its position in Legend Biotech by 1.6% during the 2nd quarter. Public Sector Pension Investment Board now owns 24,689 shares of the company’s stock worth $1,093,000 after purchasing an additional 400 shares during the period. Sei Investments Co. increased its position in Legend Biotech by 1.5% during the 2nd quarter. Sei Investments Co. now owns 46,492 shares of the company’s stock worth $2,059,000 after purchasing an additional 702 shares during the period. Vanguard Group Inc. raised its stake in shares of Legend Biotech by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 129,359 shares of the company’s stock worth $7,256,000 after buying an additional 738 shares in the last quarter. Finally, Blue Trust Inc. boosted its stake in shares of Legend Biotech by 10,075.0% in the second quarter. Blue Trust Inc. now owns 814 shares of the company’s stock valued at $36,000 after buying an additional 806 shares in the last quarter. 70.89% of the stock is owned by institutional investors and hedge funds.

Legend Biotech Price Performance

NASDAQ:LEGN opened at $41.66 on Friday. Legend Biotech Co. has a 12-month low of $36.92 and a 12-month high of $70.13. The company’s 50-day moving average is $43.95 and its two-hundred day moving average is $47.90. The firm has a market cap of $7.64 billion, a price-to-earnings ratio of -43.85 and a beta of 0.08. The company has a current ratio of 4.98, a quick ratio of 4.90 and a debt-to-equity ratio of 0.27.

Legend Biotech (NASDAQ:LEGN) last released its earnings results on Tuesday, November 12th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.22. Legend Biotech had a negative return on equity of 29.69% and a negative net margin of 66.92%. The firm had revenue of $160.20 million during the quarter, compared to analyst estimates of $143.91 million. During the same period in the prior year, the firm posted ($0.17) earnings per share. The business’s quarterly revenue was up 66.9% compared to the same quarter last year. Research analysts expect that Legend Biotech Co. will post -1.23 EPS for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $86.00 price objective on shares of Legend Biotech in a research report on Tuesday, October 29th. Scotiabank raised their price objective on shares of Legend Biotech from $70.00 to $76.00 and gave the company a “sector outperform” rating in a research note on Monday, August 12th. Redburn Atlantic initiated coverage on shares of Legend Biotech in a research report on Tuesday, October 8th. They set a “buy” rating and a $86.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $73.00 price target on shares of Legend Biotech in a research report on Wednesday, November 13th. Thirteen investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $81.46.

Legend Biotech Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).